Health Economics Summer School 2015
September 14th – September 18th, 2015
A high–level program offered by the Institute for Innovation & Valuation in Health Care in cooperation with the University of Heidelberg (Department for Public Health, Mannheim Medical Faculty).
Dr. Christian Affolter (Lucerne / Switzerland)
Executive in charge of Public Affairs & Tariff Structures at CSS Health Insurance, since 2013.
Formerly Director of the department for strategic key issues (“Grundlagen”) at santésuisse; Vice-Director and Head of department for health policy at the Federal Office of Public Health (Bundesamt für Gesundheit, BAG) in Switzerland; chairman of business unit Life Science in a consulting firm.
Prof. Gerd Antes (Freiburg / Germany1)
Chairman of the German Cochrane Centre in Freiburg, Germany.
Since 2008 member of scientific advisory board Health Technology Assessment at DIMDI (Deutsches Institut für Medizinische Dokumentation und Information/ German Institute for Medical Documentation and Information); since 2007 member of the extended executive board at DNEbM e.V. (Deutsches Netzwerk Evidenz-basierte Medizin /German Network for evidence-based medicine) and project coordinator of DRKS (Deutsches Register klinischer Studien / German register for clinical studies).
Prof. Friedrich Breyer (Konstanz / Germany)
Chair of Economic and Social Policy, University of Konstanz / Germany, Economics Department.
Chairman of the health economics committee of the association of German-speaking economists from 2006 to 2009 (Verein für Sozialpolitik); member of the advisory board of the Federal Ministry of Economics and Technology (Germany); Research Professor at the German Institute of Economic Research in Berlin; author of one of the major health economics textbooks.
Prof. Amiram Gafni (Hamilton, ON / Canada)
Professor in the Department of Clinical Epidemiology and Biostatistics at Mc Master University in Hamilton, ON / Canada, and member of the Centre for Health Economics and Policy Analysis (CHEPA).
He is a research associate with the Research Institute for Quantitative Studies in Economics and Population in the Faculty of Social Sciences at McMaster University; more than 400 publications in peer-reviewed journals in economics and the social sciences.
Prof. Silvio Garattini (Milan / Italy)
Founder of the Mario Negri Institute for Pharmacological Research and the EORTC (European Organisation for Research and Treatment of Cancer).
President of the UICC Committee on Antitumoral Chemotherapy, President of the European Organisation for Research and Treatment of Cancer (EORTC), Consultant to the World Health Organisation; Fellow of the New York Academy of Sciences, the American Association for the Advancement of Science and Honorary Fellow of the Royal College of Physicians (Pharmaceutical Medicine) in London / England.
Prof. Søren Holm (Manchester, England / UK)
Professorial Fellow in Bioethics at the University of Manchester / United Kingdom and Professor of Medical Ethics at the University of Oslo / Norway.
Member of the Danish Council of Ethics from 1994 to 1999 and former member of Nuffielc Council on Bioethics; he has been President-Elect of the European Society for the Philosophy of Medicine and Health Care; currently Vice-President of the International Association of Bioethics.
Prof. Maarten Ijzerman (Twente / Netherlands)
Professor and chair of the department for Health Technology and Services Research at the University of Twente (Netherlands).
Active ISPOR member since 2004 and a member of the Board of Directors since 2013; Co-director of the Global Initiative for Translational Health Economics (GITHE); many peer-reviewed articles in the intersection of engineering, medicine and outcomes research over the last years.
Prof. Peter Kolominsky-Rabas (Erlangen / Germany)
Professor and Director of the Interdisciplinary Centre for Health Technology Assessment (HTA) and Public Health, University of Erlangen-Nurnberg, Germany.
Member of the European Healthcare Innovation Leadership Network testing multi-stakeholder consultations in early-stage drug development ; from 2005 to 2008 Head of the Department for Health Economics at the German Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Health Care (IQWiG), Cologne / Germany.
Prof. Erik Nord (Oslo / Norway)
Senior Researcher at the Norwegian Institute of Public Health in Oslo since 2003 in the Department of Mental Health; Professor at School of Pharmacy in Oslo, Norway.
Assignments for the OECD, the WHO, and the Norwegian National Council for Priority Setting in Health Care; long-standing research interests in methods and procedures for economic evaluation and priority setting; author of an ninfluential textbook on “cost-value analysis” in health care.
Prof. Matthias Perleth (Berlin / Germany1)
Chairman of the department of specialist counselling at the German Federal Joint Committee (Gemeinsamer Bundesausschauss) for medical affairs, in Berlin, Germany.
Formerly consulting physician at the Federal Association of the German statutory health insurance, AOK, from 2001 to 2007; Associate Professor at the Technical University Berlin since 2007; author of a German textbook on Health Technology Assessment (HTA).
Prof. Ulf Persson (Lund / Sweden)
Professor in Health Economics at the Institute of Economic Research, School of Economics and Management, Lund University and Chief Executive Officer at the Swedish Institute for Health Economics (IHE).
More than 25 years research experience in the development and application of economic evaluation methods in health care, with particular regard to the introduction and utilization of medical technologies; 10 years experience as a member of the board of the Swedish pricing and reimbursement authority, the Pharmaceutical Benefit Board and at the Swedish Dental Benefit Board.
Prof. Maarten Postma (Groningen / Netherlands)
Professor in Pharmacoeconomics at the University of Groningen, Department of Pharmacy (Netherlands).
President of the section Public Health Economics of the European Public Health Association (EUPHA); he serves on the editorial boards of Expert Reviews in Pharmacoeconomics & Outcomes Research and Expert Opinions in Pharmacology.
Prof. Jeffrey Richardson (Melbourne, Australia)
Professor in the Faculty of Business and Economics at Monash University (Melbourne / Clayton, Victoria) and
Foundation Director of the Centre for Health Economics (CHE).
President of the Australian Health Economists’ Group from 1984 to 1991; former member of the Pharmaceutical Remuneraton Tribunal in Australia; member of the editorial boards of five leading health economic journals; Adjunct Associate of Stanford University and Honorary Professor at the University of South Australia.
Dr. Heiner Sandmeier (Basle / Switzerland)
Deputy Secretary General, Interpharma, and Member of the Federal Medicines Commission in Switzerland.
Member of EAK (Eidgenössische Arzneimittelkommission/ Federal Drug Commission-Switzerland), member of Governing Board at SGGP (Schweizerische Gesellschaft für Gesundheitspolitik/ Swiss Society for Health Policy) and the Suisse Delegation Working Party on Biotechnology of the OECD.
Prof. Michael Schlander (Wiesbaden / Germany)
Scientific Program Director for Heidelberg Health Economics Summer School
Founding Chairman of the Institute for Innovation & Valuation in Health Care (InnoValHC); Professor of Health Care & Innovation Management at the University of Applied Economic Sciences Ludwigshafen / Germany.
Health Economist at the Mannheim Medical Faculty of the University of Heidelberg; scientific program chair of ISPOR Annual European Congress 2012 in Berlin / Germany; author of an in-depth analysis of the NICE multiple technology appraisal process.
Dr. Oriol de Sola-Morales Serra (Barcelona / Spain)
Medical Director of Sabirmedical and Colaborator of Centre for Research in Health and Economics (CRES), Spain.
From 2007 to 2011 Director of Healthcare Technology Evaluation with the Healthcare Information, Evaluation and Quality Agency (AIAQS) belonging to the Catalan Health Service (CAHTA), where he set up and chaired the Commission for the Evaluation of Hospital-use Drugs (CAMUH).
Dr. Harry Telser (Olten / Switzerland)
An affiliated member of the Department of Economics at the University of Zürich, Switzerland.
Coordinator for computer sciences and Senior Research Fellow at socio-economic department at the University of Zürich, Head of ´Health´ at Plaut Economics, Divisional Head of ´Health´at Polynomics; author of the textbook "Measuring Benefits in the Health Care Sector – Discrete-Choice Experiments".
Keith Tolley (Buxton, England / United Kingdom)
Director of Tolley Health Economics – a company he set up in 2008 to provide strategic advice and consultancy in the area of the use of health economic analysis, HTA for the market access of pharmaceuticals.
He worked both in academia (University of York – Centre for Health Economics and University of Nottingham, UK 1987-1997), for several pharmaceutical companies, including GSK, Pfizer and Ortho Biotech (1997-2005) and in consultancy as a Director at Mapi Values.
Prof. Mondher Toumi (Lyon / France)
President and founder of Creativ-Ceutica and Professor at University Lyon I / France, department of decision sciences and health policies, where he is Chair of market access.
He worked in the laboratory of pharmacology at the University of Marseille, where he joined the Public Health Department; in 2000 he was appointed Vice President of Lundbeck in charge of economics, pricing, market access, epidemiology, risk management and competitive intelligence; he established and he conducts the first European University Diploma of Market Access (EMAUD) in Paris, France.
Prof. Friedrich von Bohlen (Heidelberg / Germany1)
Professor for Informatics and Computer Sciences at SRH Heidelberg, Germany.
Founder of Molecular Health AG, serving as its Chairman; Co-Founder of dievini GmbH and Managing Director since 2005; he also co-founded dievini Hopp BioTech holding GmbH & Co. KG, and serves as its Managing Director; he served as the Chief Executive Officer and Chairman of Management Board of Agennix AG until 2011; he also co-founded LION Bioscience AG.